| GTO ID | GTC3282 |
| Trial ID | NCT05659264 |
| Disease | Heart Failure |
| Altered gene | RLN |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA |
| Treatment | mRNA-0184 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants With Chronic Heart Failure |
| Year | 2022 |
| Country | Poland|United Kingdom|United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-0184-P101|2022-000784-46 |
| Vector information | |||
|
|||
| Cohort1: mRNA-0184_single dose | |||||||
|
|||||||
| Cohort2: mRNA-0184_up to 4 doses | |||||||
|
|||||||
| Cohort3: Placebo | |||||||
|
|||||||